EVALUATION OF GLYCATED ALBUMIN AND DYSLIPIDEMIA IN TYPE-2 DIABETES MELLITUS

Author(s): Suresh Babu Kondaveeti, Ivvala Anand Shaker, Aravind Kumar R, Hemraz palwan, Raja G

Abstract

Diabetic patients with accompanied (but often unnoticed) dyslipidemia are soft targets of cardiovascular deaths. An early intervention to normalize circulating lipids shown to reduce cardiovascular complications and mortality. Now a day’s Glycated albumin (GA) is a routinely used marker for short-term glycemic control. This investigation is an attempt to evaluate the association between GA and various lipid parameters. Venous blood samples collected from 100 type-2 diabetic patients (46 males, 44 females) and serum analyzed for GA, Fasting blood glucose, Total Cholesterol, Triacylglycerols, HDL-C and LDL-C. L/H risk ratio is also calculated. The levels of GA (%) did not differ significantly between males (8.51 ± 1.17) and females (8.24 ± 1.89), whereas male patients had higher mean values of FBG and various lipid parameters than in females. Patients with GA value >17.0 % showed direct and significant correlation with FBG, TC, LDL-C, L/H risk ratio as compared to patients with GA ≤ 17.0%. There was no significant difference in TG, HDL-C between two groups of glycated albumin. These findings indicate that GA is utilized for screening high risk diabetic patients for early diagnosis of dyslipidemia and timely intervention with lipid lowering drugs.

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.